Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Cytori and Worthington Enter Celase® GMP Distribution Agreement to Facilitate Translational Research

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the signing of a non-exclusive, 3 year distribution agreement with Worthington Biochemical Corporation for Celase® GMP enzyme for research markets in the U.S. and select international countries.

Celase® GMP is a proprietary enzyme containing a unique blend of collagenase, neutral protease and buffer salts that are produced using avian and mammalian tissue-free raw materials, aseptically processed, sterile filtered and highly purified under cGMP guidelines. Integrating Celase® GMP into cell isolation study protocols can facilitate a smooth transition from bench and animal research to downstream clinical applications.

“The addition of Cytori’s Celase® GMP product to Worthington’s Collagenase and STEMxyme® portfolio provides our customers with more options to support their unique research needs than ever before,” said Von Worthington, President and CEO at Worthington Biochemical Corporation. “We plan to offer Celase® GMP through Worthington’s catalog, direct sales force, distributor network and e-commerce website. Also, we intend to showcase the product at upcoming scientific meetings and trade shows."

“We are very excited and pleased to initiate a partnership for Celase® GMP. The goal of the partnership is to facilitate translational research in regenerative medicine using Celase® GMP and potentially broaden the number of clinical applications for Cytori Cell Therapy,” said Russ Havranek, Director of Marketing at Cytori Therapeutics.

Researchers may subscribe to celase.com to learn of product updates or send inquiries to celase@cytori.com.

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information visit www.cytori.com.

About Worthington

Worthington Biochemical develops and produces high quality purified enzymes, proteins, nucleic acids and cell isolation kits for applications in life science research, diagnostics, bioprocessing and biotechnology. Founded in 1947 and privately held, Worthington has maintained a reputation for quality products and excellent customer service. With worldwide distribution, Worthington markets products directly to domestic customers and internationally through a network of distributors. As a primary manufacturer, Worthington can meet enzyme requirements from research-scale to bulk bioprocessing quantities with all manufacturing taking place at their ISO9001 Certified facility located in Lakewood, New Jersey, USA. For more information visit www.worthington-biochem.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements that involve known and unknown risks and uncertainties. Some of these risks include preclinical, clinical and regulatory uncertainties, such as those associated with benefits of our Cytori Cell Therapy, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports. There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.

Contacts:

Cytori Therapeutics, Inc.
Tiago Girao, 858-458-0900
ir@cytori.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.